![]() |
Multi-center cabozantinib IST for hormone receptor-positive breast cancer with bone m
Exelixis, Inc. today announced the initiation of an investigator-sponsored trial of cabozantinib in women with hormone receptor-positive breast cancer with bone metastases.
More... |
| All times are GMT -7. The time now is 10:43 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021